The long-held science fiction concept of controlling digital devices with one's mind is becoming a functional reality through advancements in brain-computer interfaces (BCIs). The field gained significant public attention when Neuralink received FDA approval for its first in-human clinical study in May 2023 and has since implanted its device in a small number of patients, according to a report from Built In. This milestone signals a pivotal moment, moving BCIs from pure research toward tangible, life-altering applications that could revolutionize human interaction with technology.

Brain-computer interfaces (BCIs) create a direct communication pathway between the brain's electrical activity and external machines, interpreting neural signals to translate user intent into digital commands. These systems enable control of computers, prosthetic limbs, or other technologies without physical movement, offering potential to restore function for individuals with severe motor disabilities and to redefine human-computer interaction. Reflecting significant investment and interest, the BCI market is projected to triple from nearly $2 billion in 2023 to $6.2 billion by the end of the decade.